Dextramabs: A Novel Format of Antibody‐Drug Conjugates Featuring a Multivalent Polysaccharide Scaffold
Abstract: Antibody‐drug conjugates (ADCs) are multicomponent biomolecules that have emerged as a powerful tool for targeted tumor therapy. Combining specific binding of an immunoglobulin with toxic properties of a payload, they however often suffer from poor hydrophilicity when loaded with a high amount of toxins. To address these issues simultaneously, we developed dextramabs, a novel class of hybrid antibody‐drug conjugates. In these architectures, the therapeutic antibody trastuzumab is equipped with a multivalent dextran polysaccharide that enables efficient loading with a potent toxin in a controllable fashion. Our modular chemoenzymatic approach provides an access to synthetic dextramabs bearing monomethyl auristatin as releasable cytotoxic cargo. They possess high drug‐to‐antibody ratios, remarkable hydrophilicity, and high toxicity in vitro.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Dextramabs: A Novel Format of Antibody‐Drug Conjugates Featuring a Multivalent Polysaccharide Scaffold ; volume:8 ; number:3 ; year:2019 ; pages:354-357 ; extent:4
ChemistryOpen ; 8, Heft 3 (2019), 354-357 (gesamt 4)
- DOI
-
10.1002/open.201900066
- URN
-
urn:nbn:de:101:1-2022072806365301128716
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Other Objects (12)
Dextramabs: A Novel Format of Antibody-Drug Conjugates Featuring a Multivalent Polysaccharide Scaffold
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Antibody–drug conjugates as an emerging therapy in oncodermatology
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Dextramabs: A Novel Format of Antibody-Drug Conjugates Featuring a Multivalent Polysaccharide Scaffold
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Antibody–drug conjugates as an emerging therapy in oncodermatology
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
Dextramabs: A Novel Format of Antibody-Drug Conjugates Featuring a Multivalent Polysaccharide Scaffold
Antibody–drug conjugates in ovarian cancer
Antibody–drug conjugates—the magic bullet?
Fate of Antibody-Drug Conjugates in Cancer Cells
Antibody–drug conjugates (ADCs) in lung cancer treatment
Ethynylphosphonamidates in the Synthesis of Antibody–Drug Conjugates
Antibody–drug conjugates as an emerging therapy in oncodermatology
Safety and Tolerability of Antibody-Drug Conjugates in Cancer
Antibody–drug conjugates in the treatment of lymphoid neoplasms
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Research progress of antibody–drug conjugates in gynecologic cancer